Skip Navigation
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.


The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Your Environment. Your Health.

Publication Detail

Title: Co-Targeting Plk1 and DNMT3a in Advanced Prostate Cancer.

Authors: Zhang, Zhuangzhuang; Cheng, Lijun; Zhang, Qiongsi; Kong, Yifan; He, Daheng; Li, Kunyu; Rea, Matthew; Wang, Jianling; Wang, Ruixin; Liu, Jinghui; Li, Zhiguo; Yuan, Chongli; Liu, Enze; Fondufe-Mittendorf, Yvonne N; Li, Lang; Han, Tao; Wang, Chi; Liu, Xiaoqi

Published In Adv Sci (Weinh), (2021 Jul)

Abstract: Because there is no effective treatment for late-stage prostate cancer (PCa) at this moment, identifying novel targets for therapy of advanced PCa is urgently needed. A new network-based systems biology approach, XDeath, is developed to detect crosstalk of signaling pathways associated with PCa progression. This unique integrated network merges gene causal regulation networks and protein-protein interactions to identify novel co-targets for PCa treatment. The results show that polo-like kinase 1 (Plk1) and DNA methyltransferase 3A (DNMT3a)-related signaling pathways are robustly enhanced during PCa progression and together they regulate autophagy as a common death mode. Mechanistically, it is shown that Plk1 phosphorylation of DNMT3a leads to its degradation in mitosis and that DNMT3a represses Plk1 transcription to inhibit autophagy in interphase, suggesting a negative feedback loop between these two proteins. Finally, a combination of the DNMT inhibitor 5-Aza-2'-deoxycytidine (5-Aza) with inhibition of Plk1 suppresses PCa synergistically.

PubMed ID: 34051063 Exiting the NIEHS site

MeSH Terms: No MeSH terms associated with this publication

to Top